This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
DICE Therapeutics Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for DICE Therapeutics.
Información clave
-22.3%
Tasa de crecimiento de los beneficios
-14.8%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 23.5% |
| Tasa de crecimiento de los ingresos | 86.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 09 Aug 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 2 | -224 | -161 | -205 | 8 |
| 12/31/2024 | N/A | -169 | -161 | -155 | 9 |
| 12/31/2023 | N/A | -140 | -116 | -109 | 9 |
| 6/30/2023 | N/A | -104 | -87 | -84 | N/A |
| 3/31/2023 | N/A | -91 | -75 | -73 | N/A |
| 12/31/2022 | N/A | -84 | -67 | -64 | N/A |
| 9/30/2022 | N/A | -77 | -63 | -61 | N/A |
| 6/30/2022 | N/A | -74 | -56 | -54 | N/A |
| 3/31/2022 | 1 | -59 | -46 | -45 | N/A |
| 12/31/2021 | 1 | -49 | -40 | -39 | N/A |
| 9/30/2021 | 1 | -40 | -31 | -30 | N/A |
| 6/30/2021 | 2 | -29 | -27 | -27 | N/A |
| 3/31/2021 | 1 | -27 | -24 | -24 | N/A |
| 12/31/2020 | 1 | -24 | -21 | -21 | N/A |
| 12/31/2019 | 6 | -13 | -17 | -16 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: DICE is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: DICE is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: DICE is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: DICE is forecast to have no revenue next year.
Ingresos de alto crecimiento: DICE is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if DICE's Return on Equity is forecast to be high in 3 years time